QSAR based therapeutic management of M. tuberculosis

Area of Science:

• Medicinal Chemistry
• Computational Biology
• Pharmacology

Background:

• Tuberculosis (TB), caused by Mycobacterium tuberculosis, poses a significant global health burden, particularly in developing nations.
• The rise of multidrug-resistant tuberculosis (MDR-TB) necessitates the development of novel and effective anti-tubercular agents.
• Interdisciplinary strategies are crucial for discovering new drugs against TB.

Purpose of the Study:

• To review recent advancements in computational approaches for anti-tuberculosis drug discovery.
• To highlight the role of quantitative structure-activity relationship (QSAR) and structure-based drug design in identifying novel drug candidates.
• To discuss the future prospects of developing new anti-TB drugs through integrated computational methods.

Main Methods:

• Utilizing computer-based quantitative structure-activity relationship (QSAR) models, including 3D-QSAR.
• Employing structure-based drug design principles for ligand pose prediction and model validation.
• Screening combinatorial libraries and using molecular docking to filter potential drug molecules.
• Integrating diverse chemical and biological data into QSAR models for predicting activity and toxicity.

Main Results:

• Identification of several novel molecular entities with potential anti-tubercular activity.
• Development of statistically validated QSAR models for predicting drug efficacy and safety profiles.
• Successful application of computational screening and docking to filter candidate compounds.
• Advancements in integrating multiple data types for more comprehensive drug discovery models.

Conclusions:

• Computational methods, particularly QSAR and structure-based design, are powerful tools for accelerating anti-TB drug discovery.
• These approaches are vital for identifying new drug candidates to address the challenge of multidrug-resistant tuberculosis.
• Continued integration of advanced computational techniques holds significant promise for future anti-tuberculosis drug development.